Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry

Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no sequence homology to TPO, was developed to avoid immunogenicity...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: Mytych, Daniel T., Park, Joseph K., Kim, June, Barger, Troy E., Boshier, Andy, Jawa, Vibha, Kuter, David J.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Platelets Haemostasis and Thrombosis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540503/
https://ncbi.nlm.nih.gov/pubmed/32311075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16658
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki